NEOSTAR Results Indicate That Neoadjuvant Nivolumab Plus Ipilimumab Enhances Pathologic Responses in Operable NSCLC

Published by W Butcher on

Findings from the randomised phase II NEOSTAR study indicate that neoadjuvant treatment with nivolumab plus ipilimumab enhances pathologic responses, tumour immune infiltrates and immunologic memory in patients with operable non-small cell lung cancer (NSCLC). Tina Cascone of the Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center in Houston, TX, USA and colleagues reported the study results on 18 February 2021 in the Nature Medicine.

Read More…

Categories: Uncategorized

0 Comments

Leave a Reply

Avatar placeholder

Your email address will not be published.